[Use of activated recombinant factor VII in patients with brain injury or undergoing brain surgery].
Ingelmo Ingelmo
I
I
Rama-Maceiras
P
P
Fàbregas Julià
N
N
Hernández Palazón
J
J
D000328:Adult; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001921:Brain / Q000601:surgery*; D001925:Brain Damage, Chronic / Q000517:prevention & control; D001930:Brain Injuries / Q000150:complications*; D002543:Cerebral Hemorrhage / Q000517:prevention & control*; D002648:Child; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019635:Neurosurgical Procedures; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D011247:Pregnancy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D019851:Thrombophilia / Q000139:chemically induced / Q000150:complications
D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa